ResearcherUniversity of KentuckyActive in the last 2 years
Megan M. Harper
Matched on ORCID iD 0000-0002-2935-6292; OpenAlex author ID A5030589285. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 18
2019: 1 paper · 2020: none · 2021: none · 2022: 2 papers · 2023: none · 2024: 2 papers · 2025: 1 paper
Papers 6
- Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer. Co-author DOI 10.1002/1878-0261.70062↗
- Development of a Novel Protocol for Germline Testing in Pancreatic Cancer. Co-author DOI 10.1245/s10434-024-16011-3↗
- Treatment at an Academic Medical Center Eliminates Survival Disparities for Appalachian Kentuckians with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.13023/jah.0601.02↗
- Interaction of immune checkpoint PD-1 and chemokine receptor 4 (CXCR4) promotes a malignant phenotype in pancreatic cancer cells. Co-author DOI 10.1371/journal.pone.0270832↗
- Endogenous Pancreatic Cancer Cell PD-1 Activates MET and Induces Epithelial-Mesenchymal Transition to Promote Cancer Progression. Co-author DOI 10.3390/cancers14133051↗
- MST1R kinase accelerates pancreatic cancer progression via effects on both epithelial cells and macrophages. First author DOI 10.1038/s41388-019-0811-9↗
Closest collaborators
The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Michael J. Cavnar · 5 shared papers, 2022–2025 · strength 0.90
- Paper Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cance… DOI 10.1002/1878-0261.70062↗
- Paper Treatment at an Academic Medical Center Eliminates Survival Disparities for Appalachian Kentuckians with Pancreatic Duc… DOI 10.13023/jah.0601.02↗
- Paper Interaction of immune checkpoint PD-1 and chemokine receptor 4 (CXCR4) promotes a malignant phenotype in pancreatic can… DOI 10.1371/journal.pone.0270832↗
- Joseph Kim · 5 shared papers, 2022–2025 · strength 0.90
- Paper Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cance… DOI 10.1002/1878-0261.70062↗
- Paper Treatment at an Academic Medical Center Eliminates Survival Disparities for Appalachian Kentuckians with Pancreatic Duc… DOI 10.13023/jah.0601.02↗
- Paper Interaction of immune checkpoint PD-1 and chemokine receptor 4 (CXCR4) promotes a malignant phenotype in pancreatic can… DOI 10.1371/journal.pone.0270832↗
- Reema Anil Patel · 4 shared papers, 2022–2024 · strength 0.70
- Paper Treatment at an Academic Medical Center Eliminates Survival Disparities for Appalachian Kentuckians with Pancreatic Duc… DOI 10.13023/jah.0601.02↗
- Paper Interaction of immune checkpoint PD-1 and chemokine receptor 4 (CXCR4) promotes a malignant phenotype in pancreatic can… DOI 10.1371/journal.pone.0270832↗
- Paper Endogenous Pancreatic Cancer Cell PD-1 Activates MET and Induces Epithelial-Mesenchymal Transition to Promote Cancer Pr… DOI 10.3390/cancers14133051↗
- Hannah G. McDonald · 3 shared papers, 2024–2025 · strength 0.56
- Paper Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cance… DOI 10.1002/1878-0261.70062↗
- Paper Treatment at an Academic Medical Center Eliminates Survival Disparities for Appalachian Kentuckians with Pancreatic Duc… DOI 10.13023/jah.0601.02↗
- Paper Development of a Novel Protocol for Germline Testing in Pancreatic Cancer. DOI 10.1245/s10434-024-16011-3↗
- Mei Gao · 3 shared papers, 2022–2025 · strength 0.54
- Paper Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cance… DOI 10.1002/1878-0261.70062↗
- Paper Interaction of immune checkpoint PD-1 and chemokine receptor 4 (CXCR4) promotes a malignant phenotype in pancreatic can… DOI 10.1371/journal.pone.0270832↗
- Paper Endogenous Pancreatic Cancer Cell PD-1 Activates MET and Induces Epithelial-Mesenchymal Transition to Promote Cancer Pr… DOI 10.3390/cancers14133051↗
- Anna M. Reagan · 2 shared papers, 2024–2025 · strength 0.36
- Emily Cassim · 2 shared papers, 2024 · strength 0.36
- Erin E. Burke · 2 shared papers, 2024 · strength 0.36
- Chelsey Mckenna Williams · 1 shared paper, 2024 · strength 0.16
- Alex Cazes · 1 shared paper, 2019 · strength 0.07
- Betzaira G. Childers · 1 shared paper, 2019 · strength 0.07
- Philippe Foubert · 1 shared paper, 2019 · strength 0.07
- Michael C. Schmid · 1 shared paper, 2019 · strength 0.07
- Jeffery M. Chakedis · 1 shared paper, 2019 · strength 0.07
- Judith A. Varner · 1 shared paper, 2019 · strength 0.07
- Michele L. Babicky · 1 shared paper, 2019 · strength 0.07
- Dawn Jaquish · 1 shared paper, 2019 · strength 0.07
- Andrew M. Lowy · 1 shared paper, 2019 · strength 0.07
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.